🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Berlin
Clinical trial register · Germany

Clinical Trials in Berlin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca115 Charite University, Berlin, Germany93 Janssen Research & Development, LLC49 Eli Lilly and Company45 Novartis Pharmaceuticals45
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Berlin

1584 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
NCT06865651Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 2
44
Dresden, Berlin, Mainz, Tübingen
2025-05-22
Recruiting
Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa
NCT06940830Hemophilia A
DrugEfanesoctocog alfa
Swedish Orphan Biovitrum
Phase 4
250
Berlin, Bonn, Frankfurt am Main, Hamburg, Munich
2025-05-21
Active, closed
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479Severe Asthma
DrugVerekitug
Upstream Bio Inc.
Phase 2
396
Hamburg, Berlin, Hessen, Leipzig, Bendorf, Mainz
2025-05-21
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370Heart Failure
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
4,200
Bad Friedrichshall, Bamberg, Berlin, Bonn, Bünde, Coburg, Dresden, Erfurt
2025-05-20
Recruiting
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
NCT06890273Endometrial Cancer
AstraZeneca
Observational
150
Amberg, Bad Nauheim, Bautzen, Berlin, Bielefeld, Bonn, Borna, Bottrop
2025-05-20
Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798Delayed Graft Function, DGF, Kidney Transplant
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
450
Berlin, Erlangen, Lübeck, Mainz Am Rhein, Münster
2025-05-19
Recruiting
Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression
NCT06967857Attention-Deficit/Hyperactivity Disorder (ADHD), Depression - Major Depressive Disorder
Prof. Dr. Frank Behrens
Phase 2
105
Berlin, Bonn, Frankfurt, Leipzig, München
2025-05-15
Recruiting
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
NCT06780085Carcinoma, Non-Small-Cell Lung
DrugsR-DXd·Ifinatamab Deruxtecan
Merck Sharp & Dohme LLC
Phase 2
96
Tübingen, Berlin
2025-05-13
Recruiting
Project VERANDA: Requirement Analysis Survey
NCT07424872Observational Study
Berlin Institute of Health @ Charité
Observational
100
Berlin
2025-05-13
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
587
Berlin, Heidelberg, Mainz
2025-05-12
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
Heidelberg, Villingen-Schwenningen, Frankfurt am Main, Mainz, Dresden, Leipzig, Berlin
2025-05-08
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Immenhausen, Essen, Dresden, Baden, Berlin
2025-05-06
Recruiting
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
NCT07227246Intracerebral Hemorrhage
DrugRecombinant Factor VIIa
Joseph Broderick, MD
Phase 3
350
Heidelberg, Erlangen, Frankfurt am Main, Augsburg, Berlin, Hamburg, Tübingen
2025-05-06
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285Myelodysplastic Syndromes
DrugElritercept
Takeda
Phase 3
225
Bonn, Düsseldorf, Leipzig, Halle, Magdeburg, Berlin
2025-05-06
Recruiting
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06747351Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
DrugsTAK-881·Hyqvia
Takeda
Phase 3
59
Mannheim, Ulm, Marburg, Hanover, Berlin
2025-05-06
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab
AstraZeneca
Phase 3
1,220
Aachen, Berlin, Bonn, Dortmund, Dresden, Essen, Frankfurt, Göttingen
2025-05-06
Recruiting
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438Acute Myeloid Leukemia, Adult
DrugRevumenib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
448
Berlin, Bochum, Bonn, Braunschweig, Bremen, Darmstadt, Essen, Flensburg
2025-05-05
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
974
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Recruiting
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)
DrugsPelacarsen·Inclisiran
Novartis Pharmaceuticals
Phase 3
340
Stuttgart, Potsdam, Chemnitz, Leipzig, Berlin, Bielefeld, Gelnhausen, Mannheim
2025-04-30
Recruiting
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
NCT06538064Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
Observational
30
Rüdersdorf, Marburg, Bochum, Berlin
2025-04-29
Recruiting
International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)
NCT06186271Contraception
Center for Epidemiology and Health Research, Germany
Observational
68,100
Berlin
2025-04-24
Recruiting
Study of the Effectiveness of VRET Combined With tDCS in the Treatment of PTSD in Ukrainian Veterans and Civilians
NCT06806267PTSD - Post Traumatic Stress Disorder
Malek Bajbouj
Not applicable
100
Berlin
2025-04-22
Recruiting
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869Insomnia Disorder
DrugTasimelteon
Vanda Pharmaceuticals
Phase 3
420
Berlin, Leipzig
2025-04-21
Active, closed
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145Hypertension, Pulmonary
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
440
Heidelberg, München, Giessen, Cologne, Mainz, Dresden, Berlin
2025-04-16
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
DrugsIcotrokinra·Ustekinumab
Janssen Research & Development, LLC
Phase 3
752
Augsburg, Bad Bentheim, Berlin, Bonn, Bramsche, Darmstadt, Dresden, Friedrichshafen
2025-04-15
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab
Corcept Therapeutics
Phase 2
270
Aachen, Berlin, Kempten
2025-04-11
Recruiting
Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function
NCT06943469Atopic Dermatitis (AD)
Société des Produits Nestlé (SPN)
Not applicable
400
Berlin, Düsseldorf, Frankfurt, Spandau, Wesel
2025-04-10
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671CLL, Chronic Lymphocytic Leukemia
DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax
BeOne Medicines
Phase 3
250
Augsburg, Berlin, Chemnitz, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-04-10
Recruiting
A Clinical Study of Arfolitixorin in Patients With mCRC
NCT06922383Metastatic Colorectal Cancer (mCRC)
Isofol Medical AB
Phase 1/2
90
Berlin, Essen, München
2025-04-10
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
DrugsRilvegostomig·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
830
Amberg, Augsburg, by, Bad Saarow, Berlin, Bonn, Braunschweig, Essen, Flensburg
2025-04-10
Recruiting
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
869
Magdeburg, Berlin, Deggingen
2025-04-09
Active, closed
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
NCT06921850Hidradenitis Suppurativa
DrugBimekizumab
UCB Biopharma SRL
Phase 3
43
Berlin
2025-04-07
Active, closed
Exploratory Clinical Study on Fasting in Psoriasis and Psoriatic Arthritis (RiseFast)
NCT06905028Psoriasis Arthritis, Psoriasis (PsO)
Charite University, Berlin, Germany
Not applicable
30
Berlin
2025-04-04
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan
Gilead Sciences
Phase 3
695
Berlin, Bochum, Chemnitz, Esslingen am Neckar, Hamburg, Löwenstein, Minden, Munich
2025-04-04
Active, closed
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
NCT06910358Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
DrugBitopertin
Disc Medicine, Inc
Phase 3
183
Berlin, Chemnitz
2025-04-04
Active, closed
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
NCT07108166COPD, Smoking, Tobacco Use
Philip Morris Products S.A.
Not applicable
290
Berlin, Delitzsch, Hanover, Karlsruhe, Leipzig, Neu-Isenburg, Offenbach, Reinfeld
2025-04-02
Not yet open
A Multicenter Prospective Observational Study on Vertebral Fracture Risk Stratification in Patients With Vertebral Metastases
NCT06910618Vertebral Metastases, Vertebral Fracture
Buda Health Center
Observational
300
Berlin
2025-04-01
Recruiting
Troubled-Desire & Therapeutic Chat for Reduction of CSAM Use (TD-CHAT)
NCT06852443Prevention, Well Being, Sexual Behavior, Behavior Change
Charite University, Berlin, Germany
Not applicable
180
Berlin
2025-04-01
Not yet open
Pre-Operative Treatment in REseCTable COlon CanceR
NCT06899477Colo-rectal Cancer, Colon Cancer, Colon Carcinoma
DrugsMFOLFOXIRI·MFOLFOX6·Folfox·Irinotecan
Dominik Paul Modest
Phase 3
714
Berlin, Berlin-Spandau, Chemnitz, Cologne, Dessau, Dortmund, Frankfurt, Hamburg
2025-04
Recruiting
Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II
NCT06615102Cardiac Surgery, Vasoplegia
DrugsAngiotensin II·Noradrenalin
Universität Münster
Phase 3
1,022
Berlin, Bonn, Mainz, Münster
2025-03-31
Recruiting
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289Eosinophilic Asthma
AstraZeneca
Phase 3
400
Berlin, Bonn, Cottbus, Delitzsch, Frankfurt am Main, Geesthacht, Hemer, Landsberg
2025-03-28
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
NCT06867094Colitis Ulcerative
DrugSAR441566
Sanofi
Phase 2
204
Berlin, Duisburg, Frankfurt, Hanover, Tübingen, Ulm
2025-03-28
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Berlin, Chemnitz, Cologne, Donauwörth, Erfurt, Gauting, Georgsmarienhütte, Großhansdorf
2025-03-27
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
DrugsTaxotere·Rilvegostomig·Paraplatin·Taxol
AstraZeneca
Phase 3
600
Berlin, Chemnitz, Dessau, Dresden, Düsseldorf, Essen, Hamburg, Kassel
2025-03-27
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel
Daiichi Sankyo
Phase 3
510
Berlin, Bonn, Dresden, Frankfurt am Main, Hamburg, Jena, Leipzig, Nuremberg
2025-03-27
Active, closed
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
NCT06731803Esophagogastric Adenocarcinoma
DrugTrastuzumab deruxtecan
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1/2
36
Berlin, Chemnitz, Essen, Frankfurt am Main, Halle, Hamburg, Heidelberg, Jena
2025-03-25
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsEfti·Pemetrexed·Keytruda·Paclitaxel
Immutep S.A.S.
Phase 3
756
Amberg, Augsburg, Bad Saarow, Berlin, Cologne, Frankfurt, Frankfurt am Main, Gauting
2025-03-21
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
565
Freiburg im Breisgau, Würzburg, Frankfurt am Main, Düsseldorf, Merzig, Leipzig, Bad Bentheim, Berlin
2025-03-20
Active, closed
A Study of Navenibart in Participants With Hereditary Angioedema
NCT06842823Hereditary Angioedema (HAE)
DrugNavenibart
Astria Therapeutics, Inc.
Phase 3
157
Berlin, Frankfurt, Hanover
2025-03-20
Recruiting
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662Chronic Inflammatory Demyelinating Polyneuropathy
Immunovant Sciences GmbH
Phase 2
162
Berlin, Bochum, Essen, Tübingen, Ulm, Würzburg
2025-03-18
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
DrugTezepelumab
AstraZeneca
Phase 3
990
Bendorf, Berlin, Haltern am See, Hanover, Immenhausen, Lübeck, Marburg, Rosenheim
2025-03-18
Active, closed
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
DrugMaridebart cafraglutide
Amgen
Phase 3
1,105
Aachen, Bad Krozingen, Bad Mergentheim, Bad Oeynhausen, Berlin, Elsterwerda, Essen, Falkensee
2025-03-17
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
600
Berlin, Frankfurt, Halle, Hanover, Jena, Mannheim, Ulm
2025-03-17
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
DrugsAbraxane·Paraplatin·Taxol·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
1,000
Erlangen, Düsseldorf, Essen, Saarbrücken, Leipzig, Berlin
2025-03-16
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Aachen, Amberg, Bad Homburg, Bad Oeynhausen, Bamberg, Bechhofen, Berlin, Bochum
2025-03-14
Active, closed
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
3,853
Aachen, Bad Homburg, Bad Krozingen, Bad Mergentheim, Bad Oeynhausen, Berlin, Dresden, Elsterwerda
2025-03-12
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)
DrugsBMS-986393·Carfilzomib·Pomalidomide·Daratumumab
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Munich, Hanover, Chemnitz, Leipzig, Magdeburg, Kiel, Berlin, Hamburg
2025-03-12
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab
AstraZeneca
Phase 2
80
Berlin, Dresden, Essen, Hamburg, Marburg
2025-03-12
Recruiting
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT06668181Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
DrugBimekizumab
UCB Biopharma SRL
Phase 3
40
Berlin, Dresden, Freiburg im Breisgau, Hamburg, Sankt Augustin, Sendenhorst, Tübingen
2025-03-11
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
DrugRimegepant
Pfizer
Phase 3
723
Schwerin, Berlin
2025-03-11
Recruiting
Application of Plant Protection Products (PPP) in Apple Orchards
NCT06884189Dermal Exposure, Inhalative Exposure, Metabolites in Urine, Effekt Biomarker in Blood
German Federal Institute for Risk Assessment
Observational
16
Berlin
2025-03-11
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
600
Leipzig, Magdeburg, Berlin, Hamburg, Herne
2025-03-10
Recruiting
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
NCT06806033Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
DrugsGlofitamab·Obinutuzumab·Oxaliplatin·Gemcitabine
Hoffmann-La Roche
Phase 2
130
Berlin, Cologne, Magdeburg
2025-03-05
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
5,000
Bad Homburg, Bamberg, Berlin, Bochum, Brandenburg an der Havel, Dresden, Essen, Friedrichsthal
2025-03-03
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,088
Bad Bentheim, Bad Doberan, Ratingen, Leipzig, Berlin, Dresden, Hamburg, München
2025-03-03
Active, closed
Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
NCT06680622Metastatic Gastro-esophageal Adenocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
126
Aachen, Amberg, Augsburg, Bad Saarow, Berlin, Bielefeld, Chemnitz, Dortmund
2025-03-03
Active, closed
Clinical Study to Predict the Risk of Bone Fractures With the POROUS Ultrasound Device
NCT06567054Healthy, Osteopenia, Osteoporosis
POROUS GmbH
Not applicable
1,600
Berlin, Halle, Marburg
2025-03-03
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil
AstraZeneca
Phase 3
840
Augsburg, Bad Saarow, Berlin, Braunschweig, Chemnitz, Düsseldorf, Erlangen, Essen
2025-03-01
Recruiting
Amplitude-modulated Radiofrequency Electromagnetic Field Treatment for Advanced Hepatocellular Carcinoma (Immune-RF)
NCT06821958Hepatocellular Carcinoma (HCC)
Charite University, Berlin, Germany
Not applicable
36
Berlin
2025-03-01
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 3
600
Aachen, Bad Bentheim, Berlin, Bochum, Bonn, Buxtehude, Darmstadt, Dortmund
2025-02-28
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
DrugBW-20805
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Mainz, Berlin
2025-02-28
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Berlin, Chemnitz, Dresden, Frankfurt am Main, Hamburg, Heidelberg, Leipzig, München
2025-02-27
Active, closed
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323Small Cell Lung Cancer (SCLC)
DrugTarlatamab
Amgen
Phase 2
252
Berlin, Homburg, Kiel, Würzburg
2025-02-26
Recruiting
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
NCT07558668Moderate to Severe Atopic Dermatitis
Sitryx Therapeutics Ltd
Phase 1
149
Berlin, Frankfurt, Freiburg im Breisgau
2025-02-26
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
552
Bad Bentheim, Berlin, Dresden, Freiburg im Breisgau, Hamburg, Herne, Langenau, Minden
2025-02-21
Recruiting
Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock
NCT05726825Septic Shock
Hannover Medical School
Not applicable
274
Berlin, Bonn, Braunschweig, Bremerhaven, Cologne, Erlangen, Essen, Halle
2025-02-19
Recruiting
HappyMums Mobile Application Study
NCT06578845Pregnancy, Antenatal Depression
King's College London
Observational
1,000
Berlin
2025-02-18
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
231
Berlin, Frankfurt, Hamburg, Landsberg, Münster, Tübingen, Wiesbaden, Würzburg
2025-02-12
Recruiting
Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants
NCT06823466Ischemic Stroke, Oral Anticoagulation, Atrial Fibrillation (AF), Outcome Assessment
University of L'Aquila
Observational
200
Berlin, Halle
2025-02-12
Recruiting
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
NCT06686615Primary Hypercholesterolemiia, Mixed Dyslipidemia
DrugsBempedoic acid·Ezetimibe·Rosuvastatin·Atorvastatin
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
2,000
Aachen, Ahaus, Alsfed, Bad Homburg, Berlin, Burg, Chemnitz, Detmold
2025-02-12
Active, closed
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053Asthma
DrugGSK5784283
GlaxoSmithKline
Phase 2
307
Bendorf, Berlin, Darmstadt, Frankfurt, Fürstenwalde, Leipzig, Magdeburg, Mainz
2025-02-10
Active, closed
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236Platinum-resistant Ovarian Cancer
DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Genmab
Phase 3
530
Berlin, Bonn, Dresden, Düsseldorf, Essen, Frankfurt, Giessen, Hamburg
2025-02-07
Recruiting
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670Pyoderma Gangrenosum
DrugsSpesolimab·Prednisolone·Prednisone
LEO Pharma
Phase 3
90
Berlin, Düsseldorf, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Tübingen, Würzburg
2025-02-05
By invitation
A Multicenter, International, Prospective and Retrospective, Follow-up Registry to Monitor the Efficacy and Safety of the Occlutech Paravalvular Leak Device (PLD) in Patients With Mitral or Aortic Paravalvular Leaks
NCT07037446Paravalvular Leak
Occlutech International AB
Observational
200
Berlin, Dresden, München
2025-02-05
Recruiting
LEOPARD Training and Validation Data Collection Study
NCT06675604Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
Assistance Publique - Hôpitaux de Paris
Observational
4,500
Aachen, Berlin, Hanover, Jena, Kiel, Leipzig, Münster, Tübingen
2025-02-04
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355Extensive-stage Small-cell Lung Cancer
DrugsPumitamig·Etoposide·Atezolizumab·Carboplatin
BioNTech SE
Phase 3
621
Berlin, Bonn, Chemnitz, Esslingen am Neckar, Gauting, Gera, Großhansdorf, Halle
2025-02-03
Recruiting
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
NCT06821880Chronic Lymphocytic Leukaemia (CLL), Multiple Myeloma (MM), Secondary Immunodeficiency (SID)
Medical University Innsbruck
Observational
120
Berlin, Garmisch-Partenkirchen
2025-02-03
Active, closed
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
NCT06812325Thyroid Eye Disease (TED)
DrugVRDN-003
Viridian Therapeutics, Inc.
Phase 3
320
Berlin, Essen, Göttingen, Mainz
2025-02-03
Recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563Glioblastoma
DrugsTemozolomide·Keytruda·Pembrolizumab
NovoCure GmbH
Phase 3
741
Berlin, Essen, Frankfurt
2025-02-03
Recruiting
Cyclosporine In Takotsubo Syndrome
NCT05946772Takotsubo Cardiomyopathy
DrugCyclosporine A
University Hospital Heidelberg
Phase 2
204
Bad Nauheim, Berlin, Bonn, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2025-02-01
Recruiting
Prospective Assessment Project of AirwaY Management-related Incidents in Adult Anaesthesia Care PAPAYA III
NCT06117176Airway Complication of Anesthesia, Adverse Events
Insel Gruppe AG, University Hospital Bern
Observational
40,000
Berlin, Hamburg
2025-02-01
By invitation
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06679881Hereditary Angioedema (HAE)
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 3
170
Berlin, Frankfurt, Munich
2025-02-01
Recruiting
Family-based Telemedicine vs. Inpatient Anorexia Nervosa Treatment (FIAT)
NCT06759402Anorexia Nervosa, Anorexia in Adolescence
Charite University, Berlin, Germany
Not applicable
200
Berlin
2025-01-31
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
588
Langenau, Darmstadt, Dresden, Halle, Berlin, Bochum, Bonn, Erlangen
2025-01-31
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Frankfurt am Main, Bochum, Mainz, Dresden, Leipzig, Berlin
2025-01-29
Active, closed
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595Generalized Anxiety Disorder
DrugDT120
Definium Therapeutics US, Inc.
Phase 3
245
Berlin, Mannheim, Tübingen
2025-01-29
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Aachen, Berlin, Braunschweig, Chemnitz, Dresden, Düsseldorf, Essen, Göttingen
2025-01-28
Recruiting
Colorectal Resections in Patients With Retroperitoneal Sarcoma
NCT06943612Sarcoma, Soft Tissue, Retroperitoneal Sarcoma
Heidelberg University
Observational
120
Mannheim, Göttingen, Berlin, Cologne, Dresden, Erlangen, Greifswald, Halle
2025-01-27
Rows per page Showing 401–500 of 1584
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/berlin?page=5

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,584 of those studies with a site in Berlin.

How many clinical trials are recruiting in Berlin?

844 of the 1,584 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 47 have not yet opened recruitment, 660 are active but closed to new participants, and 33 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.